Dexcom Inc Stock Price, News & Analysis

Dexcom (NASDAQ:DXCM) will launch the Dexcom G7 15 Day continuous glucose monitoring system in the U.S. on Dec. 1, 2025 for people 18 and older, initially through durable medical equipment (DME) providers with full retail availability to follow.

The system offers an industry-leading 15.5 days of sensor wear, an overall MARD of 8.0% for accuracy, Medicare coverage and meets therapeutic CGM category requirements. A study showed 73.9% of sensors lasted the full 15 days while ~26% may not. G7 15 Day connects with select automated insulin delivery systems and adds app features like Apple Watch connectivity, automated activity and medication logging, and a 12-hour replacement grace period.

Dexcom (NASDAQ: DXCM) announced on November 19, 2025 that the FDA cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults 18+ with Type 2 diabetes using glargine U-100 long-acting insulin.

Dexcom Smart Basal uses Dexcom G7 15 Day sensor data plus logged doses to deliver personalized daily dose recommendations and reminders in the G7 15 Day app, and connects with Dexcom Clarity for provider prescribing and configuration. Availability in the US will follow the product launch; international rollout is being explored.

Dexcom (NASDAQ: DXCM) unveiled 16 global diabetes advocates for its World Diabetes Day campaign on November 14, 2025.

The advocates — selected from ~1,000 open-call submissions — span ages 6 to 68, represent Type 1, Type 2 and prediabetes, and come from four continents and five countries. The campaign highlights personal stories and use of Dexcom glucose biosensing technology via editorial portraits and a Los Angeles photoshoot that included visits from Lance Bass and Retta.

More details and individual stories are available at Dexcom.com/WorldDiabetesDay.

Dexcom (NASDAQ: DXCM) announced that as of November 7, 2025 Québec will expand RAMQ coverage to include Dexcom Continuous Glucose Monitoring (CGM) for eligible adults (age 18+) living with type 2 diabetes who are treated with intensive insulin therapy (IIT).

Eligibility requires IIT (at least three injections/day or insulin pump) plus one or more clinical criteria such as unmet HbA1C targets, frequent hypoglycemia, or impaired hypoglycemia awareness. The release highlights Dexcom G7 features including a 30-minute warm-up, predictive Urgent Low Soon alert (3.1 mmol/L within 20 minutes), waterproof rating (submerged up to eight feet for 24 hours), and Apple Watch connectivity.

Dexcom (Nasdaq: DXCM) reported third quarter 2025 results on October 30, 2025 with revenue up 22% YoY to $1.209 billion (20% organic). The company raised full‑year 2025 revenue guidance to $4.630–$4.650 billion (≈15% growth) and updated margin targets: non‑GAAP gross margin ~61%, non‑GAAP operating margin ~20–21%, and adjusted EBITDA margin ~29–30%. GAAP operating income rose to $242.5 million (20.1% of revenue), up 480 bps year‑over‑year. Strategic items included an AI meal‑logging feature, expanded G7 access in Ontario, submission of Dexcom Smart Basal to FDA, and Stelo surpassing $100 million revenue in its first year. Cash, cash equivalents and marketable securities totaled $3.32 billion.

Dexcom (NASDAQ:DXCM) announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.

Dr. Ashley serves as Chair of the Department of Medicine at Stanford, overseeing 15 divisions and over 800 faculty. His work spans precision medicine, data science, AI, and digital health. He has co-founded seven biotechnology companies and co-directs Stanford’s biomedical innovation-translation program, Catalyst.

Dexcom said Dr. Ashley will provide a clinical perspective for strategic guidance on medical technology development and healthcare innovation. Quotes from Eric Topol and President/interim CEO Jake Leach highlight his fit with Dexcom’s growth and focus on advancing metabolic health.

Dexcom (NASDAQ:DXCM) has scheduled its third quarter 2025 earnings release and conference call for October 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time.

Investors can access the conference call via webcast through Dexcom's investor relations website at investors.dexcom.com, or by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114".

Dexcom (NASDAQ:DXCM), a leader in glucose biosensing, will present significant innovations and clinical evidence at the 61st EASD Conference. The company will introduce Dexcom Smart Basal, a new integrated titration module currently under FDA and CE mark review, designed to simplify basal insulin management.

Key clinical findings include: reduced neonatal complications in gestational diabetes using CGM versus fingersticks, optimized glucose control through exercise timing in pregnant Type 1 diabetes patients, and a 65% reduction in hypoglycemic events when switching from fingersticks to Dexcom CGM. New cost-effectiveness data from Japan demonstrates CGM's superiority over fingersticks for Type 2 diabetes patients on insulin therapy.

Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched its first open call for diabetes advocates in the U.S. and Canada. The initiative invites individuals aged 2 and older living with all types of diabetes and prediabetes to apply through September 19, 2025, for a chance to be featured in Dexcom's 2025 World Diabetes Day campaign.

Selected candidates will participate in a Los Angeles photoshoot and receive ongoing support from Dexcom throughout the year to attend events and connect with the diabetes community. The campaign is supported by Nick Jonas, multi-platinum recording artist and diabetes advocate. Applications can be submitted at Dexcom.com/WorldDiabetesDay until September 19 at 12 p.m. PDT.